Study on Cancer Vaccine 105AD7 for Colorectal Cancer
Author Information
Author(s): Maxwell-Armstrong C A, Durrant L G, Buckley T J D, Scholefield J H, Robins R A, Fielding K, Monson J R T, Guillou P, Calvert H, Carmichael J, Hardcastle J D
Primary Institution: Division of Gastrointestinal Surgery, University Hospital, Queens Medical Centre, Nottingham, UK
Hypothesis
Does the anti-idiotypic monoclonal antibody 105AD7 improve survival in patients with advanced colorectal cancer compared to placebo?
Conclusion
The study found that 105AD7 vaccination does not prolong survival in patients with advanced colorectal cancer.
Supporting Evidence
- 162 patients were enrolled in the study.
- Median survival was 124 days for the 105AD7 group and 184 days for the placebo group.
- Compliance with treatment was poor, with only 50% receiving the planned vaccinations.
Takeaway
The cancer vaccine 105AD7 didn't help people with advanced colorectal cancer live longer than those who didn't get the vaccine.
Methodology
A randomized, double-blind, placebo-controlled survival study was conducted with 162 patients receiving either 105AD7 or placebo.
Limitations
Poor compliance with treatment and high tumor burden in the patient population may have affected the results.
Participant Demographics
Patients with advanced colorectal cancer, with 50% having malignancy in at least 2 anatomic sites.
Statistical Information
P-Value
0.38
Statistical Significance
p=0.38
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website